ArticleBMC infectious diseases2025
Seroprevalence of Immunoglobulin M and G antibodies to severe acute respiratory syndrome coronavirus 2 infection in Iwo, Nigeria.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIn many countries, the preliminary stage of the COVID-19 pandemic has reached its climax and serological studies are extremely important in managing public health responses to the COVID-19 pandemic caused by SARS-CoV-2. The Nucleocapsid protein, a highly immunogenic protein, found only in infected individuals is important in SARS-CoV-2 infection. This study was therefore designed to determine the seroprevalence of SARS-CoV-2 IgM and IgG antibodies to nucleocapsid proteins in Iwo, Nigeria, thereby providing information on the spread of the infection.
methodsFive millilitres of blood were collected from 360 individuals visiting four selected hospitals in Iwo, Nigeria. Socio-demographic and clinical data of the participants were obtained through a structured questionnaire. SARS-CoV-2 IgM and IgG antibodies against the nucleocapsid protein were detected from plasma samples using commercially available Enzyme-linked Immunoassay kits (Monobind Inc, USA) according to the manufacturer's instructions. Statistical analyses were performed using SPSS software version 21 at P < 0.05 for statistical significance.
resultsOut of the tested samples, 37 and 165 were positive for IgM and IgG antibodies giving a prevalence of 10.3% [95% CI: 7.5% - 13.6%] and 45.8% [95% CI: 40.8% - 50.8%], respectively. In total, 184 samples tested positive for SARS-CoV-2 antibodies giving an overall prevalence of 51.1% [95% CI: 45.8% - 56.1%]. Infection was associated with age; older population (35-90 years), fever, cough and muscle pain (p < 0.05). SARS-CoV-2 IgM and IgG antibodies were detected among 11.8% and 42.6% of COVID-19 vaccine recipients, respectively.
conclusionsHigh seroprevalence of SARS-CoV-2 antibodies to nucleocapsid proteins were detected among the study population. In particular, is detecting IgM antibodies among those who have received COVID-19 vaccines. This reveals a high level of recent and past exposure to SARS-CoV-2 virus infection and continuous spread within the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.